Drug intelligence / Profile preview

SGN-2FF + pembrolizumab

Development stage: Discontinued
Lead developer: Pfizer
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

SGN-2FF + pembrolizumab is a combination therapy consisting of SGN-2FF, a potent small-molecule inhibitor of glycoprotein fucosylation, and pembrolizumab, an immune checkpoint inhibitor targeting PD-1. This first-in-human, first-in-class combination was investigated for the treatment of advanced solid tumors. SGN-2FF works by inhibiting fucosylation of glycoproteins, while pembrolizumab enhances T-cell immune responses against tumor cells by blocking the PD-1 pathway.

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on SGN-2FF + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SGN-2FF + pembrolizumab.

Explore the full profile